Associations between Variants in IL-33/ST2 Signaling Pathway Genes and Coronary Heart Disease Risk

International Journal of Molecular Sciences

Fangqin Wu¹  Mei𠆚n He²  Qiang Wen¹  Wencai Zhang¹  Jinhua Yang¹  Xiaomin Zhang²  Tangchun Wu²  Longxian Cheng¹ 

[1] Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Dadao, Wuhan 430022, China; E-Mails:;Institute of Occupational Medicine and the Ministry of Education, Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 HangKong Road, Wuhan 430030, China; E-Mails:

关键词: coronary artery disease;    ST2;    IL-33;    IL-1RAcP;    signaling pathway;    gene;   

DOI  :  10.3390/ijms151223227

来源: mdpi

【 摘 要 】

The IL-33/ST2 signaling pathway plays an important role in coronary artery disease (CHD); however, few studies have explored how variants in IL-33/ST2 genes influence CHD risk. Here, we examined the association between genetic variants in IL-33, ST2, and IL-1RAcP of the IL-33/ST2 axis and the risk of CHD. We conducted a case-controlled study with 1146 CHD cases and 1146 age- and sex-frequency-matched controls. Twenty-eight single nucleotide polymorphisms (SNPs) in IL-33, ST2, and IL-1RAcP were genotyped by Sequenom MassArray and TaqMan assay. Logistic regression was used to analyze these associations. The SNP rs4624606 in IL-1RAcP was nominally associated with CHD risk. The AA genotype was associated with a 1.85-fold increased risk of CHD (95% confidence interval (CI) = 1.01–3.36; p = 0.045) compared to the TT genotype. Further analysis showed that AA carriers also had a higher risk of CHD than TT + TA carriers (odds ratio (OR) = 1.85; 95% CI = 1.85–3.35; p = 0.043). However, no significant association was observed between variants in IL-33/ST2 genes and CHD risk. Further studies are needed to replicate our results in other ethnic groups with larger sample size.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.